Leading Cardiovascular Researcher And PAD Treatment Pioneer, Dr. Christopher Kevil, To Chair JanOne Scientific Advisory Board
LAS VEGAS, Jan. 16, 2020 /PRNewswire/ -- JanOne Inc. (NASDAQ:JAN) appoints Christopher Kevil, Ph.D., a pioneer in nitrite based PAD treatment, to lead its scientific advisory board.In this role, Dr. Kevil will chair the Company's scientific advisory board to advise on drug development and technology strategy, assist with clinical research, and help to advance its lead candidate TV1001SR, for the treatment of PAD.
- LAS VEGAS, Jan. 16, 2020 /PRNewswire/ -- JanOne Inc. (NASDAQ:JAN) appoints Christopher Kevil, Ph.D., a pioneer in nitrite based PAD treatment, to lead its scientific advisory board.In this role, Dr. Kevil will chair the Company's scientific advisory board to advise on drug development and technology strategy, assist with clinical research, and help to advance its lead candidate TV1001SR, for the treatment of PAD.
- Most notable, is Dr. Kevil's research that led to the development and formulation of TV1001SR, a nitrite based treatment for PAD which has shown positive results in phase 2a trials.
- "We are thrilled to have Chris lead our Scientific Advisory board, and look forward to his contributions," said Tony Isaac, CEO of JanOne.
- JanOne is a unique NASDAQ-listed company offering innovative, actionable solutions that it believes can help create an end to the opioid crisis.